Table 1.
Psychotropic medications of patients with MDD during the ECT series
| All patients (n = 30) | Female patients (n = 12) | Male patients (n = 18) | |
|---|---|---|---|
|
Age, mean, ±SD
range |
57.1, ±17.7 25–85 |
71.1 ± 12.2 45–85 |
45.2 ± 17.0 25–79 |
|
Total number of ECTs, mean, ±SD
range |
10.4, ±3.6 5–17 |
10.8 ± 4.3 5–17 |
8.2 ± 3.6 5–13 |
| Psychotic symptoms | 14 | 7 | 7 |
| First episode of MDD | 9 | 4 | 5 |
| Recurrent MDD | 21 | 13 | 8 |
| Antidepressants | |||
| SSRI | 9 | 3 | 6 |
| SNRI | 12 | 5 | 7 |
| Mirtazapine | 12 | 6 | 6 |
| Bupropion | 4 | 1 | 3 |
| Antipsychotics | |||
| Second‐generation antipsychotics | 28 | 11 | 17 |
| Conventional neurolepts | 1 | 0 | 1 |
| Anxiolytics | |||
| Benzodiazepines | 21 | 8 | 13 |
| Pregabalin | 2 | 2 | 0 |
| Buspirone | 1 | 0 | 1 |
SNRI: serotonin and norepinephrine reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor.